Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência.

June 19, 2020June 19, 2020

Computer Model Seen to Accurately Distinguish PAH From PVOD

News, PAH News

Gene expression patterns in the lungs can help distinguish pulmonary arterial hypertension (PAH) from pulmonary veno-occlusive disease (PVOD) — a subtype in which the narrowing of veins, instead of ... Read more

June 15, 2020June 15, 2020

Aerami, Vectura Sign Deal to Develop Nebulized Imatinib

News, PAH News

Aerami Therapeutics has entered an agreement with Vectura Group to develop and commercialize an inhaled form of imatinib — an approved cancer therapy — for the treatment of people ... Read more

June 3, 2020June 3, 2020

Voice Biomarker May Aid in Remote Monitoring for Heart Failure Risk

News, PH News

A composite assessment of voice features may be able to monitor changes in the pulmonary arteries of people with pulmonary hypertension (PH) who are at risk of heart failure, ... Read more

May 22, 2020May 22, 2020

Nicotine Inhaled Often, as with E-cigarette Use, Linked to PH in Mice

News, PH News

Chronic inhalation of nicotine, the addictive component of all tobacco products, is enough to trigger changes in pulmonary arteries and in the heart’s right chamber that can cause pulmonary ... Read more

April 20, 2020April 20, 2020

LENUS Pro Pump for Remodulin May Need Monitoring of Flow Rate

News, PAH News

Tricumed‘s LENUS Pro pump, an implantable device approved in Europe for the long-term intravenous administration of Remodulin (treprostinil) to treat pulmonary arterial hypertension (PAH), does not maintain a steady flow ... Read more

April 13, 2020April 13, 2020

Acceleron’s Sotatercept Granted FDA’s Breakthrough Therapy Status for PAH

News, PAH News

The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to Acceleron Pharma‘s investigational molecule sotatercept for the treatment of pulmonary arterial hypertension (PAH). Breakthrough designation is given ... Read more

April 8, 2020April 8, 2020

Sex Hormones Not Found to Play a Role in PAH Development in Single-Center Study

News, PAH News

Despite previous evidence to the contrary, a single-center study suggests that sex hormones do not influence the development or progression of pulmonary arterial hypertension (PAH), nor do they explain ... Read more

September 1, 2016September 1, 2016

In Certain CTEPH Patients, Vascular Remodeling May Lead to Hypoxemia

News

Patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are successfully treated with pulmonary endarterectomy (PEA) may be at increased risk of having low levels of oxygen in the blood ... Read more

August 30, 2016August 30, 2016

Pulmonary Hypertension Seen as Prevalent Among HIV-infected Patients in Africa

News

People infected with HIV are known to have a greater incidence of pulmonary hypertension and to be an almost 2,500-fold higher risk of developing PH than others, and a new study ... Read more

August 26, 2016August 26, 2016

Vascular Constrictor Seen as Target in Treating Pulmonary Arterial Hypertension

News, PAH News

The vascular constrictor coupling factor 6 (CF6) is involved in the development of pulmonary arterial hypertension by creating an imbalance in the inner lining of lung blood vessels, part of ... Read more

Pin It on Pinterest